628711-48-8

Basic information

• Product Name: 3-bromo-4-(cyclopropylmethoxy)benzaldehyde
• Synonyms: 3-bromo-4-(cyclopropylmethoxy)benzaldehyde
• CAS NO: 628711-48-8
• Molecular Weight: 255.111
• Mol File: 628711-48-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-bromo-4-(cyclopropylmethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-4-(cyclopropylmethoxy)benzaldehyde(628711-48-8)
• EPA Substance Registry System: 3-bromo-4-(cyclopropylmethoxy)benzaldehyde(628711-48-8)

Safety Data

• Hazardous Substances Data: 628711-48-8(Hazardous Substances Data)

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 7051-34-5 cyclopropylcarbinyl bromide 

Downstream Products

• 1268511-91-6 2-bromo-1-(cyclopropylmethoxy)-4-(difluoromethyl)benzene 
• 1268511-98-3 2-[2-(cyclopropylmethoxy)-5-(difluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1254062-54-8 (3-bromo-4-cyclopropylmethoxyphenyl)methanol 

Relevant articles and documents

METHYLPYRROLOPYRIMIDINECARBOXAMIDES

The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES

The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.